Brentuximab vedotin shows extended survival in Hodgkin lymphoma patients

12/16/2013 | Healio (free registration)

Brentuximab vedotin, an antibody drug conjugate that binds to the protein CD30, showed promising benefits in a midstage trial involving 102 patients with Hodgkin lymphoma who received autologous stem cell transplants. About 10% of the study participants achieved long-term remission, raising the possibility that the drug may be curative for a subset of patients, said the University of Washington's Dr. Ajay Gopal.

View Full Article in:

Healio (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA